Cochlear confirms its hearing implant systems will still enter the US duty-free, following the US government’s latest Section 301 investigation findings. US authorities announced fresh tariffs of 10% or 12.5% on goods from 60 trading partners, citing failures to block products linked to forced labour. Those measures fall under Section 301 of the Trade Act, which targets specific trade practices deemed unfair. Cochlear’s products avoid the new charges, preserving a key cost advantage in a major market.
Section 301 investigations examine the acts, policies and practices of different economies, focusing on imports suspected of being produced with forced labour. The new tariffs apply to countries that, according to US authorities, have not effectively prohibited such imports. By retaining duty-free access, Cochlear sidesteps sudden cost inflation that could have hit its US pricing and margins. The outcome is especially important because the US is a critical growth engine for the hearing implant business.
Market pressure on Cochlear has already been intense after the company cut its full-year profit guidance in April. The downgrade was driven by weaker consumer sentiment, particularly in the US, which reduced demand expectations. Shares sold off sharply after that warning, reflecting investor concern about both growth and profitability. Avoiding extra US import costs now removes one more potential drag on earnings at a time when sentiment is already fragile.
